# An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia

> **NCT02970929** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Development & Commercialization, Inc.** · enrollment: 157 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** SEP-363856

## Key facts

- **NCT ID:** NCT02970929
- **Lead sponsor:** Otsuka Pharmaceutical Development & Commercialization, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-31
- **Primary completion:** 2019-01-29
- **Final completion:** 2019-01-29
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970929, "An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT02970929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*